Ambulatory heart failure management in private practice in France

被引:20
作者
Komajda, M
Bouhour, JB
Amouyel, P
Delahaye, F
Vicaut, E
Croce, I
Rougemond, E
Vuittenez, F
Leutenegger, E
机构
[1] Hop La Pitie Salpetriere, Serv Cardiol, F-75013 Paris, France
[2] CHU Nantes, Serv Cardiol, F-44093 Nantes 1, France
[3] Inst Pasteur, Unite Epidemiol, F-59019 Lille, France
[4] Hop Cardiovasc & Pneumol, F-69394 Lyon 03, France
[5] Hop Fernand Widal, Serv Biophys, F-75010 Paris, France
[6] Lipha Sante, F-69379 Lyon 08, France
[7] MediSCAN, F-75002 Paris, France
关键词
ambulatory; heart failure; management;
D O I
10.1016/S1388-9842(01)00172-6
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Management of ambulatory heart failure was assessed in a group of 600 patients, mean age 73, 64% males, NYHA I: 9%; II: 52%; III: 33%; IV: 6%; followed up by a representative sample of private cardiologists. Fifty-two percent of patients had been previously hospitalised for worsening heart failure with a mean duration of stay of 13.1 days, for those hospitalised in the year preceding the survey (26%). First diagnosis of heart failure had been performed by a cardiologist (57%), a general practitioner (37%) or another category of physician (6%). Seventy percent of patients received three or more different classes of heart failure medications. Diuretics were prescribed to 71%, angiotensin converting enzyme inhibitors to 54% and digitalis to 35% of the population. Beta-blockers were given to only 14% of the patients. In patients aged over 80 years, only 45% received angiotensin converting enzyme inhibitors. Conclusion: This survey of ambulatory heart failure patients confirms that the disease is predominantly observed in elderly patients, and associated with prolonged and recurrent hospitalisations. The underuse of recommended therapeutic classes including angiotensin converting enzyme inhibitors and beta-blockers deserves further investigation. (C) 2001 European Society of Cardiology. All rights reserved.
引用
收藏
页码:503 / 507
页数:5
相关论文
共 33 条
[1]
Angiotensin converting enzyme (ACE) inhibitors and heart failure -: The consequences of underprescribing [J].
Andersson, F ;
Cline, C ;
Rydén-Bergsten, T ;
Erhardt, L .
PHARMACOECONOMICS, 1999, 15 (06) :535-550
[2]
CLINICAL AND ECONOMIC-FACTORS IN THE TREATMENT OF CONGESTIVE-HEART-FAILURE [J].
ANDREWS, R ;
COWLEY, AJ .
PHARMACOECONOMICS, 1995, 7 (02) :119-127
[3]
CHILDS M, 1999, LETT PHARM, V13, P90
[4]
Cline Charles M.J., 1996, Am J Geriatr Cardiol, V5, P10
[5]
A national survey of heart failure in French hospitals [J].
Cohen-Solal, A ;
Desnos, M ;
Delahaye, F ;
Emeriau, JP ;
Hanania, G .
EUROPEAN HEART JOURNAL, 2000, 21 (09) :763-769
[6]
*CONSENSUS TRIAL S, 1987, NEW ENGL J MED, V316, P1235
[7]
Heart failure - Implications of the true size of the problem [J].
Dargie, HJ ;
McMurray, JJV ;
McDonagh, TA .
JOURNAL OF INTERNAL MEDICINE, 1996, 239 (04) :309-315
[8]
Delahaye F, 1998, ARCH MAL COEUR VAISS, V91, P1307
[9]
Differences between primary care physicians and cardiologists in management of congestive heart failure: Relation to practice guidelines [J].
Edep, ME ;
Shah, NB ;
Tateo, IM ;
Massie, BM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (02) :518-526
[10]
Erhardt LR, 1998, LANCET, V352, P15